Liminatus Pharma, Inc. Class A Common Stock (LIMN) vs Pulmatrix, Inc. (PULM)
A side-by-side comparison of Liminatus Pharma, Inc. Class A Common Stock and Pulmatrix, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
LIMN
Liminatus Pharma, Inc. Class A Common Stock
$3.70HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
PULM
Pulmatrix, Inc.
$1.43HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — LIMN vs PULM
growth of $100 · dividends reinvested · last 1yLIMN -98.4% (-98.4%/yr)PULM -77.2% (-77.2%/yr)PULM compounded faster over this window
Log scale — wide-divergence pair
LIMN PULM
LIMN vs PULM: by the numbers
- •PULM is the larger company ($5M vs $5M market cap).
Metrics side by side
Valuation
| Metric | LIMN | PULM |
|---|---|---|
| P/B ratio | 16.53 | 3.28 |
Profitability
| Metric | LIMN | PULM |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -4165.92% | -156.94% |
| ROIC | -225.12% | -160.81% |
Growth (annualized)
| Metric | LIMN | PULM |
|---|---|---|
| Total return CAGR (5Y) | N/A | -37.13% |
Go deeper
Dig into the metrics
Liminatus Pharma, Inc. Class A Common Stock ROEPulmatrix ROELiminatus Pharma, Inc. Class A Common Stock operating marginPulmatrix operating marginLiminatus Pharma, Inc. Class A Common Stock revenue growthPulmatrix revenue growthLiminatus Pharma, Inc. Class A Common Stock free cash flowPulmatrix free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.